Registration is now open!
Program directors will be able to register their fellows for $100 a fellow now through April 18, 2010.
For more information
Endocrine Society Responds to Senate Finance Committee Report on Avandia
The Endocrine Society urges the FDA to formally reconsider the concerns about the safety of the drug rosiglitazone (Avandia) by re-convening the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) to reassess the drug's safety.
Read the full Society statement...